Kyntra Bio Finalizes Roxadustat Phase 3 Protocol; Q2 Net Income $12.0M

Kyntra Bio reported significant progress in its clinical pipeline and financial results for Q2 2026. The company finalized the Phase 3 protocol for roxadustat in lower-risk myelodysplastic syndromes (LR-MDS) and expects to initiate the study in 4Q 2026. Enrollment continues for the Phase 2 monotherapy trial of FG-3246 in metastatic castration-resistant prostate cancer (mCRPC), with interim analysis on track for 4Q 2026. Financially, Kyntra Bio achieved a net income from continuing operations of $12.0 million ($2.96 EPS) for Q2 2026, a substantial improvement from a net loss of $13.7 million in the prior year, despite total revenue from continuing operations being $(1.5) million. The company reported $95.7 million in cash and equivalents, projecting sufficient funds into 2028.